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Lipid mediators in allergy: Link between human and animal models
We have changed the design of the website and of the printed
version of Allergology Internationalwith this issue, Vol. 64, No.1, ac-
cording to the start of production and hosting by Elsevier B.V. We
believe that our readers will ﬁnd the new design to be more attrac-
tive and informative. In the present issue, we offer a set of review
articles entitled “Lipid Mediators in Allergy: Link between Human
and Animal Models” that focuses on our goal of understanding
the role of lipid mediators in allergy, as well as original articles
and letters to the editor. Additionally, Professor Taniguchi has writ-
ten an obituary for Prof. Kazuo Akiyama, who passed away on
November 3rd of this year.1 Prof. Akiyama served as the president
of the Japanese Society of Allergology from 2009 to 2013. He was
the authority on research on bronchial asthma induced by fungus
such as Candida albicans and Aspergillus and also contributed to
the epidemiology of adult asthma in Japan. His death is a great
loss to those who knew him and to all of us working in this ﬁeld.
Allergy is regulated by a variety of mediators, such as cytokines.
Lipid mediators, important modulators in allergy, exert their phys-
iological functions by acting on their own G protein-coupled recep-
tors. Phospholipase (PL)A2 is a group of enzymes that hydrolyze
phospholipids to release fatty acids and lysophospholipids, which
serve as precursors for lipid mediators. Among the PLA2 superfam-
ily, secreted PLA2 (sPLA2) enzymes comprise the largest subfamily,
including 11 isoforms. Individual sPLA2 enzymes exhibit unique tis-
sue and cellular localizations and speciﬁc enzymatic properties.
Recent studies using transgenic and knockout mice for individual
sPLA2 isoforms have revealed their involvement in various patho-
physiological functions.2 Drs. Murakami and Taketomi survey the
updates on sPLA2s, especially their roles in mast cells in allergy.3
Prostanoids, which include prostaglandin (PG) and throm-
boxane, are metabolites of arachidonic acid through the action of
PLA2 released by various stimuli.4 The balance between the pro-
duction of each prostanoid and the expression of its receptors is
important for maintaining homeostasis and in the development
of pathological conditions, such as allergy.5,6 Dr. Honda and others
review the recent ﬁndings on the roles of prostanoids in allergy,
especially focusing on atopic dermatitis and asthma.7
Leukotrienes (LTs), including LTB4 and the cysteinyl LTs (CysLTs),
LTC4, LTD4 and LTE4, are generated from arachidonic acid. LTB4 is a
potent chemoattractant for leukocytes,8,9 whereas CysLTs are bron-
choconstrictors.10 LTs play a central role in the pathogenesis of
asthma and many other inﬂammatory diseases.11,12 Drs. Liu and
Yokomizo update us on the synthesis, biological function, and rele-
vance of LTs to the pathobiology of allergic diseases.13
On the other hand, omega-3 fatty acids, docosahexaenoic acid
(DHA) and eicosapentaenoic acid (EPA), are found naturally in
ﬁsh oil and are considered to be anti-inﬂammatory nutrients,
with protective effects in inﬂammatory diseases, including asthma
and allergy.14 Specialized pro-resolving mediators (protectins,
resolvins, and maresins) are generated from omega-3 fatty acids,
which counter-regulate airway eosinophilic inﬂammation and pro-
mote the resolution of inﬂammation in vivo.15 In this issue, Drs.
Miyata and Arita focus on omega-3 fatty acids and offer recent
insights into their bioactive metabolites, including resolvins and
protectins.16
Because most lipid mediators are not chemical stable, they act
locally. Therefore, lipid mediators can be good therapeutic targets
with limited side effects. In fact, lipid mediators, including non-
inﬂammatory anti-inﬂammatory drugs, PGE2, PGI2, thromboxane
A2, CysLTs, and EPA, are already clinically available. For this issue,
pioneers and experts in this ﬁeld were chosen to write updates
on lipid mediators in allergy, which may lead to links between hu-
man and animal models. We hope that the readers of this issue will
appreciate the value of looking at the pathogenesis of allergy from
the perspective of animal models and clinical relevance, and the
idea that allergy can be controlled in the future by modulating lipid
mediators.
Among the contributors to this issue, Tsukuya et al. validate a
COPD screening questionnaire, Population Screener (COPD-PS),
as an efﬁcient screening method for COPD, based on the Hisayama
study, a famous epidemiological study in Japan.17 The prevalence
of COPD is high worldwide, though it is a preventable and treat-
able disease. Therefore, some simple screening system to identify
COPD subjects would be quite valuable. Several questionnaire sys-
tems (e.g., by the IPAG guidelines), including COPD-PS, are avail-
able. Although the validity of COPD-PS has already been
established in the US, it has yet not been done in Japan. This is
the ﬁrst study aimed at validating COPD-PS in Japan, targeting
2357 subjects.
Minami et al. evaluate the diagnostic usefulness of measuring
serum IgE responding to Der p 1 and Der p 2 for house dust mite
(HDM)-speciﬁc reactivity in asthma patients.18 Crude mite extract
is used to measure serum-speciﬁc IgE and in skin prick tests as
standard tests for allergy diagnosis; however, since crude extract
contains various components, cross-reactivity independent of
HDM-reactivity becomes problematic. The ability of serum IgE to
discriminate HDM-speciﬁc reactivity was greater in Der p 1 and
Der p 2 than was crude mite extract. This suggests the usefulnessPeer review under responsibility of Japanese Society of Allergology.
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of this component of major mite proteins in diagnostic assays for
HDM reactivity.
We offer our appreciation to all the authors for their contribu-
tions to the present issue of Allergology International.
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